Clinical Trials on Bone Marrow Neoplasm in United States

Total 57172 results

Theriva Biologics, Inc.
Washington University School of Medicine

Recruiting

SYN-004 Safety and Tolerability in Allo-HCT Subjects

121121000119106, Acute Graft-versus-host Reaction Following Bone Marrow Transplant (Disorder)

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

P1101 in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Terminated

Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

Leukemia

United States
Office of Rare Diseases (ORD)
Rare Diseases Clinical Research Network

Unknown

Identifying Characteristics of Bone Marrow Failure Syndromes

Myelodysplastic Syndromes | Purpura, Thrombocytopenic | Anemia, Aplastic | Red-Cell Aplasia, Pure | Bone Marrow Failure Syndromes | Hemoglobinuria, Paroxysmal | Leukemia, Lymphocytic

United States
National Institutes of Health Clinical Center (CC)

Completed

Comparison of Quality of Life in Patients Undergoing More Intensive Versus Less Intensive Chemotherapy and Radiation Preceding a Bone Marrow Transplant

Bone Marrow Transplantation

United States
Actuate Therapeutics Inc.

Completed

Actuate 1901: 9-ING-41 in Myelofibrosis

Myelofibrosis

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myelodysplastic Syndrome | Clonal Cytopenia of Undetermined Significance

United States
Zimmer Biomet

Completed

SCP® Observational Study of the Knee

Bone Marrow Edema

United States
NS Pharma, Inc.

Completed

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Aplastic Anemia | Paroxysmal Hemoglobinuria, Nocturnal

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Myelodysplastic Syndromes | Leukemia | Congenital Amegakaryocytic Thrombocytopenia | Severe Congenital Neutropenia | Diamond-blackfan Anemia

United States
New York Blood Center

Terminated

New York Blood Center National Cord Blood Program

Lymphoma | Leukemia | Myelodysplasia | Genetic Disease | Severe Aplastic Anemia

United States
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Myelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Germany, United States, Australia, Italy, United Kingdom
Paul Szabolcs

Recruiting

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT (HSCT+RIC)

Congenital Bone Marrow Failure Syndromes | Inflammatory Conditions | Primary Immunodeficiency (PID) | Inherited Metabolic Disorders (IMD) | Hereditary Anemias | Systemic Juvenile Idiopathic Arthritis (sJIA)

United States
M.D. Anderson Cancer Center
Incyte Corporation

Completed

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Rush University Medical Center
Celgene Corporation

Terminated

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

MDS

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
CTI BioPharma

Terminated

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
S*BIO

Terminated

SB1518 for Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Leukemia

United States
Washington University School of Medicine
American Society of Hematology

Recruiting

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

Myelodysplastic Syndromes | Whole Genome Sequencing

United States
Brown University
Memorial Hospital of Rhode Island; Roger Williams Medical Center

Terminated

Decitabine, Cytarabine, GCSF for Refractory AML/MDS

Leukemia | Myelodysplasia

United States
University of Washington

Recruiting

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Secondary Myelofibrosis | Myeloproliferative Neoplasm, Unclassifiable

United States
M.D. Anderson Cancer Center

Completed

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Leukemia

United States
M.D. Anderson Cancer Center
GlaxoSmithKline; Novartis

Completed

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders

United States
Masonic Cancer Center, University of Minnesota

Completed

Stem Cell Transplant for Bone Marrow Failure Syndromes

Diamond-Blackfan Anemia | Shwachman-Diamond Syndrome | Kostmann's Neutropenia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); American Stem Cell, Inc.

Completed

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Lymphoma | Leukemia | Transplantation Infection | Blood And Marrow Transplantation | Transplantation, Bone Marrow

United States
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Completed

Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Hematologic Malignancy | Myeloproliferative Disorder

United States
University of Rochester

Not yet recruiting

A Telehealth Advance Care Planning Intervention (TeleSICP)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Myeloid Malignancy | Myelodysplastic/Myeloproliferative Neoplasm

United States
Washington University School of Medicine
Shwachman Diamond Syndrome Foundation; Barnes-Jewish Hospital

Recruiting

Diabetes/ Endocrine Surveillance in SDS

Shwachman-Diamond Syndrome

United States
Samus Therapeutics, Inc.

Terminated

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States
University of California, San Francisco

Completed

Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients

Sickle Cell Disease | Hemoglobinopathies | Thalassemia | Hematologic Malignancies | Immunodeficiencies | Fanconi's Anemia | Nonmalignant Diseases | Genetic Inborn Errors of Metabolism

United States
M.D. Anderson Cancer Center
Bayer; Celgene; Onyx Therapeutics, Inc.

Completed

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Leukemia

United States
Mikkael Sekeres, MD
Bristol-Myers Squibb; Celgene

Recruiting

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

Myelodysplastic Syndromes

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Tissue Sample Collection From Patients With Fanconi Anemia

Unspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Fanconi Anemia

United States
Syntara
Parexel

Recruiting

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Myelofibrosis

Taiwan, Australia, Korea, Republic of, United States
Fallon Clinic

Completed

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Anemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
M.D. Anderson Cancer Center
Teva Pharmaceuticals USA

Completed

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Leukemia

United States
M.D. Anderson Cancer Center

Terminated

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and...

Terminated

Study of Velcade and Thalidomide in Patients With Myelodysplasia

Myelodysplastic Syndrome

United States
Boston Children's Hospital
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaborators

Recruiting

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (TransIT)

Severe Aplastic Anemia

United States
University of Washington

Completed

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Completed

The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies

Lymphoma | Healthy | Chronic Myeloid Leukemia | Hematologic Neoplasm

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Cholecalciferol in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
M.D. Anderson Cancer Center
Amgen

Terminated

Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia

Leukemia

United States

Clinical Trials on Bone Marrow Neoplasm in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations